Longmont, CO / ACCESSWIRE / September 16, 2014 / MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane") a medical cannabis company focused on the wholesale sales and distribution of smokeless medical cannabis products, is pleased to announce MediStrips are now available for sale at in dispensaries' around Sacramento, CA.
Further to MediJane's California expansion plan and launch of its MediStrips product line, MediJane is pleased to announce that "MediStrips" are now available for sale at Medical cannabis dispensaries in the Sacramento CA area.
"We are excited to commence the rollout of MediStrips in locations around northern California, broadening our customer base and enabling medical cannabis users access to our discrete delivery systems. Over the last few months we've been focusing on expanding our sales and my personal focus has remained on increasing sales." stated Ron Lusk, Chief Executive Officer of MediJane.
About MediJane Holdings Inc. (MJMD)
MediJane is in the business of marketing and distributing products within the medical marijuana industry, including transdermal patches, capsules, sublingual sprays, oral strips, and other medical delivery systems as part of its strategic alliances with Phoenix Bio Pharmaceuticals Corporation (www.phoenixbiopharmaceuticals.com). With sales offices opening in California and Colorado, and a planned expansion into a national footprint, MediJane products are designed to give doctors the ability to provide patients accurate and effective doses of cannabinoids to manage and treat pain and other specific illnesses. MediJane's products, including the non-drowsy "Daytime Pain plus CBD" oral capsule, the CannaMist cannabinoid spray, and MediStrip Relaxation oral strips, have been formulated for the treatment of inflammation and chronic, neuropathic, arthritic, and back pain. These smokeless alternatives provide accurate dosages and are part of MediJane's launch into the chronic pain management market. Any and all medically oriented statements have not been evaluated by the Food and Drug Administration.
For more information, visit www.medijane.co
Investor Contact:
MediJane Holdings Inc.
(855) 964-7233 (Toll-free)
E-mail: [email protected]
Website: www.medijane.co
Disclaimer/Safe Harbor: Some information in this MediJane press release constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to, known and unknown risks, uncertainties and other factors which could cause MediJane's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in MediJane's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to MediJane herein are expressly qualified in their entirety by the above-mentioned cautionary statement. MediJane disclaims any obligation to update forward-looking statements contained in this press release, except as may be required by law.
SOURCE: MediJane Holdings Inc.